Return to Results

The Effect of Vaginal Progesterone Administration in the Prevention of Preterm Birth in Women With a Short Cervix [Vaginal Progesterone Bioadhesive Gel (Prochieve)® Extending Gestation A New Therapy f

new search

Trial Conditions
  • Preterm Delivery
  • Short Cervix
  • Short Uterine Cervical Length
What is the purpose of this trial?

The purpose of this research study is to evaluate the usefulness of progesterone vaginal gel in decreasing the preterm birth rate in a population of pregnant women with short cervical length and at high risk for preterm birth.

Date & Status


Who can Participate?


15  - 45 



Inclusion Criteria:

1. The subject has a short cervical length by transvaginal ultrasound (TVU) defined as
10-20mm. In cases of "dynamic cervix", the shortest observed/documented cervical
length by TVU is to be used as the cervical length for inclusion purposes.

2. Singleton gestation.

3. The pregnancy has an estimated gestational age between 19 0/7 weeks and 23 6/7 weeks.

4. Maternal age between 15 (or local age of majority/emancipation) and 45 years of age
at the time of screening. An alternative age range can be accepted according to the
standards and applicable regulations of the study centers.

5. The subject speaks either English or a common local language.

6. The subject has voluntarily signed the Informed Consent Form and associated forms
after having the contents explained, and all her questions are answered to her
satisfaction and understanding.

7. In the opinion of the investigator, the subject is able to understand the study and
is able to give informed consent, as well as participate in it and adhere to study

Exclusion Criteria:

1. The subject has a cervical length <10 or >20mm.

2. The subject has a multifetal gestation.

3. The subject has or is scheduled to have a cervical cerclage prior to randomization.
According to ACOG Practice Bulletin Number 48 (November 2003), cerclage can be
considered in a subject with a history of 3 or more unexplained midtrimester
pregnancy losses or preterm deliveries.228,229

4. Subjects diagnosed to have acute cervical insufficiency with bulging membranes
passing the external os.

5. The subject has a previous history of an adverse reaction to progesterone or any
component present in Prochieve® 8% vaginal gel.

6. The subject has been treated with a progestogen within the previous 4 weeks.

7. The subject is currently being treated for a seizure disorder, has an unstable
psychiatric disorder, is taking antihypertensive therapy for chronic hypertension at
the time of enrollment, has a history of congestive heart failure or chronic renal
failure, or has uncontrolled diabetes mellitus (known end-organ dysfunction secondary
to vascular disease).

8. The subject has active thrombophlebitis or a thromboembolic disorder, or a history of
hormone-associated thrombophlebitis or thromboembolic disorders.

9. The subject has active liver dysfunction or disease.

10. The subject has known or suspected malignancy of the breast or genital organs.

11. The subject is currently participating in another interventional study or has
participated in an interventional drug study within one month prior to screening for
this study.

12. The subject's current pregnancy is complicated by a major fetal anomaly or known
chromosomal abnormality.

13. The subject has a uterine anatomic malformation (bicornuate uterus, septate uterus)

14. The subject, in the judgment of the investigator, will be unable or unwilling to
comply with study-related assessments and procedures.

15. The subject currently has preterm rupture of membranes, vaginal bleeding, known or
suspected amnionitis, or signs or symptoms of preterm labor at the time of

16. The subject is HIV positive with a CD4 count of <350 cells/mm3 and is receiving more
than one (1) medication to prevent the transfer of AIDS to the fetus.

17. Complete placenta previa.

Gender: Female
Steward Physician(s)
  • George W. Creasy, MD, FACOG
  • Roberto Romero, MD
  • Sonia Hassan, MD
  • St. Elizabeth's Medical Center - Completed
Trial Interventions
  • progesterone
  • placebo
Physician Researcher

Investigator Name:

  • George W. Creasy, MD, FACOG
  • Roberto Romero, MD
  • Sonia Hassan, MD

Other Information

Sponsor: Juniper Pharmaceuticals, Inc.
Phase: Phase 3
Trial ID: NCT00615550
Volunteers:  Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2015 Steward Health Care
Connect Healthcare Panacea CMS Solutions